A clinical trial update dated September 18, 2026 reports on a study titled "Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors." This Phase 1 study, registered as NCT04234568, is listed with a status of active, not recruiting as of the update date.
The trial evaluates the addition of Triapine to Lutetium Lu 177 Dotatate, a radiation-based treatment approach relevant to neuroendocrine tumors, a disease area connected to somatostatin receptor targeting. The current record does not report results or outcome data for this study.
Somatostatin itself is classified as unapproved for research use and is not the subject drug being tested in this trial, but it is relevant background given the mechanism of somatostatin receptor based therapies used in neuroendocrine tumor treatment. No efficacy or safety conclusions are provided in this update.
The status designation of active, not recruiting indicates the study is ongoing but is not currently enrolling new participants. No additional trial phases, dates, or findings were included in this record beyond what is listed here. Readers can consult the compound overview for further context on somatostatin.